In this issue:
Tight control management for CD
Impact of vedolizumab on extra-intestinal manifestations of IBD
Switching from infliximab innovator to biosimilar in IBD
Donor microbiota composition important in FMT for UC
Depression associated with more aggressive IBD
Peripheral eosinophilia in IBD defines aggressive phenotype
Ethnicity influences IBD phenotype and outcomes
7-year outcomes after infliximab withdrawal in CD
Biologicals for IBD during pregnancy do not affect infants’ responses to vaccines
FODMAPs exacerbate functional GI symptoms in IBD
Please login below to download this issue (PDF)